Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCI-32765 (Ibrutinib) in CLL/SLL Patients >65 or with 17p Deletion
NCT01500733Phase 2Active, not recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Jan 2012
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by National Heart, Lung, and Blood Institute. Started Jan 2012; status: active, not recruiting.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT01500733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01500733.